TET2 and acute myeloid leukemia: There is potential value in advocating TET2 mutational or protein expression profiling in elderly patients with AML, where disease is more likely to have evolved from TET2 clonal hematopoiesis and therefore likely to be enriched for AML with biallelic TET2 mutations and null for expression (20).